ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2544

Psoriatic Arthritis Impact of Disease (PSAID12) in Early Psoriatic Arthritis: Pain As One of the Main Determinants of Disease Impact

Kim Wervers1, Jolanda J. Luime2, Ilja Tchetverikov3, Andreas H. Gerards4, Marc R Kok5, Cathelijne W. Y. Appels6, Wiebo L. van der Graaff7, Johannes H. L. M. van Groenendael8, Lindy-Anne Korswagen9, Jozien Veris10, J.M.W. Hazes2 and Marijn Vis2, 1Erasmus Medical Centre, Rotterdam, Netherlands, 2Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, 3Albert Schweitzer Hospital, Dordrecht, Netherlands, 4Sint Franciscus Vlietland Group, Schiedam, Netherlands, 5Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, 6Rheumatology, Amphia Hospital, Breda, Netherlands, 7Rheumatology, Rivas hospital, Gorinchem, Netherlands, 8Rheumatology, Reumazorg Zuid West Nederland, Roosendaal, Netherlands, 9Sint Franciscus Vlietland Group, Rotterdam, Netherlands, 10Rheumatology, Reumazorg Zuid West Nederland, Goes, Netherlands

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: pain, psoriatic arthritis and quality of life

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The Psoriatic Arthritis Impact of Disease 12-item questionnaire (PsAID12) has been developed to measure impact of Psoriatic Arthritis (PsA) for purposes of monitoring and clinical management. We aim to investigate the relation between change in disease activity and change in PsAID, and which domains of the PsAID are main drivers of change in score.

Methods: Newly diagnosed PsA patients were included in the Dutch southwest Early Psoriatic Arthritis cohoRt (DEPAR). For this analysis, patients that have answered the PsAID12 (range 0-10) at two consecutive visits (i.e. 3 months apart) within the first year were included. In case longer periods per patients were available, data from the first period of three months was used. The change in PsAID was compared to the change in disease activity over this period, measured with the Composite Psoriatic Disease Activity Index (CPDAI) using Spearman’s correlation. Change in score on PsAID domains was analyzed in subgroups of patients that perceived improvement in health and those that perceived worsening. The Short Form-36 question on self-perceived change in health was used to determine these subgroups.

Results: 143 unique patients had at least one period with two PsAID and CPDAI measurements (Table 1). Mean age was 51 (SD 13.7) and 70 (49%) were male. The difference in PsAID score was significantly but moderately correlated with the difference in CPDAI (Spearman’s rho 0.267, P=0.0013). 58 patients (41%) reported a better health status compared to 3 months ago and 29 worsening of health status. Figure 1 shows that improved patients had higher scores in almost all domains, with the biggest improvement in pain. Domains of skin problems and embarrassment/shame did not improve significantly. Worsened patients only had significantly lower scores in fatigue, discomfort and social domains.

Conclusion:  Improvement in CPDAI disease activity was significantly but moderately associated with improvement in PsAID score. This reflects that the PsAID partially measures disease activity, but measures other constructs of disease as well. In early PsA, a state of improved health is reflected in the PsAID in almost all domains, with the strongest effect in pain.

 


Disclosure: K. Wervers, None; J. J. Luime, None; I. Tchetverikov, None; A. H. Gerards, None; M. R. Kok, None; C. W. Y. Appels, None; W. L. van der Graaff, None; J. H. L. M. van Groenendael, None; L. A. Korswagen, None; J. Veris, None; J. M. W. Hazes, None; M. Vis, None.

To cite this abstract in AMA style:

Wervers K, Luime JJ, Tchetverikov I, Gerards AH, Kok MR, Appels CWY, van der Graaff WL, van Groenendael JHLM, Korswagen LA, Veris J, Hazes JMW, Vis M. Psoriatic Arthritis Impact of Disease (PSAID12) in Early Psoriatic Arthritis: Pain As One of the Main Determinants of Disease Impact [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/psoriatic-arthritis-impact-of-disease-psaid12-in-early-psoriatic-arthritis-pain-as-one-of-the-main-determinants-of-disease-impact/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/psoriatic-arthritis-impact-of-disease-psaid12-in-early-psoriatic-arthritis-pain-as-one-of-the-main-determinants-of-disease-impact/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology